5 results about "Thrombotic disorder" patented technology

This invention relates to a compound for treating thrombotic diseases. Specifically, this invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, or its enantiomer, diastereomer, transtransferase, racemic mixture, polymorph thereof, solvate thereof, or isotopically labeled derivative thereof. The compound of this invention specifically binds to the SH3 domain protein of Src kinase, interfering with the binding of integrin αIIbβ3 to Src kinase, thereby selectively inhibiting outward-to-inward signal transduction without affecting inward-to-outward signal transduction. This allows the compound of this invention to exert antithrombotic effects without affecting normal physiological hemostasis, avoiding bleeding side effects, and thus becoming a new generation of effective drugs for the prevention and treatment of thrombosis-related cardiovascular and cerebrovascular diseases.

The present disclosure relates to methods for treating or preventing a thrombotic disorder in a subject in need thereof, comprising administering to the subject in need thereof a therapeutically effective amount of zalunfiban, or a pharmaceutically acceptable salt thereof, wherein the subject has renal impairment.

The present disclosure relates to 5-amino-2, 3-dihydro-1, 4-phthalazindiones and pharmaceutically acceptable salts thereof for use in the prevention or treatment of thrombotic disorders. In particular, the invention relates to the use of a sodium salt of 5-amino-2, 3-dihydro-1, 4-phthalazindione for this purpose. Pharmaceutical compositions, advantageous techniques of formulation, and methods of treatment are disclosed.

A protease-resistant ADAMTS13 mutant protein or nucleic acid encoding the ADAMTS13 mutant protein is provided. The ADAMTS13 mutant protein comprises a mammalian ADAMTS13 protein in which one or more protease cleavage sites within the protein are replaced with amino acid sequence that is resistant to protease cleavage, and the mutant protein retains von Willebrand factor (VWF)-cleaving activity. The protease-resistant ADAMTS13 mutant is useful as a thrombolytic agent to treat common thrombotic disorders, including stroke, myocardial infarction, venous thromboembolism, and rare microvascular thrombotic disorders like thrombotic thrombocytopenia purpura (TTP).

The invention discloses an application of 4-octyl itaconic acid in preparation of a medicine for preventing and / or treating thrombotic diseases. A large number of experiments prove that 4-octyl itaconic acid can prevent and treat thrombus induced by carrageenan and relieve endothelial injury caused by endotoxin, expression of adhesion factors and inflammatory factors in endothelial cells and generation of active oxygen can be reduced, and the 4-octyl itaconic acid is small in drug toxicity, high in safety and free of toxic and side effects. The compound has a wide application prospect in clinical prevention and treatment of thrombotic diseases.